Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Portola Pharma (PTLA)

Portola Pharma (PTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,269,980
  • Shares Outstanding, K 77,819
  • Annual Sales, $ 40,130 K
  • Annual Income, $ -350,220 K
  • 60-Month Beta 2.08
  • Price/Sales 54.39
  • Price/Cash Flow N/A
  • Price/Book 8.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.60
  • Number of Estimates 4
  • High Estimate -0.44
  • Low Estimate -0.79
  • Prior Year -1.04
  • Growth Rate Est. (year over year) +42.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.77 +8.44%
on 11/15/19
31.25 -7.10%
on 11/06/19
+1.72 (+6.30%)
since 10/18/19
3-Month
25.56 +13.58%
on 10/02/19
31.52 -7.90%
on 09/13/19
+0.14 (+0.48%)
since 08/20/19
52-Week
14.81 +96.02%
on 12/24/18
37.95 -23.50%
on 04/05/19
+9.75 (+50.57%)
since 11/20/18

Most Recent Stories

More News
SmarTrend Watching for Potential Pullback in Shares of Portola Pharmace After 2.28% Gain

Portola Pharmace (NASDAQ:PTLA) traded in a range yesterday that spanned from a low of $28.21 to a high of $29.03. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high...

PTLA : 29.03 (-0.48%)
Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary anticoagulant...

PTLA : 29.03 (-0.48%)
After Yesterday's Decline of 1.45%, Portola Pharmace Offers Investors Better Value

Portola Pharmace (NASDAQ:PTLA) traded in a range yesterday that spanned from a low of $27.14 to a high of $27.97. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of...

PTLA : 29.03 (-0.48%)
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.

JNJ : 135.94 (+0.83%)
TRIL : 0.33 (+17.74%)
PTLA : 29.03 (-0.48%)
PCRX : 44.20 (+2.98%)
Look for Shares of Portola Pharmace to Potentially Pullback after Yesterday's 8.28% Rise

Portola Pharmace (NASDAQ:PTLA) traded in a range yesterday that spanned from a low of $28.35 to a high of $31.25. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high...

PTLA : 29.03 (-0.48%)
Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss

Mallinckrodt (MNK) misses on sales but beats on earnings in the third quarter of 2019.

PTLA : 29.03 (-0.48%)
LCI : 8.91 (-1.00%)
FGEN : 37.79 (+0.37%)
MNK : 3.00 (+2.74%)
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will be presented...

PTLA : 29.03 (-0.48%)
Portola Pharmaceuticals (PTLA) Reports Q3 Loss, Tops Revenue Estimates

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 35.37% and 6.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

PTLA : 29.03 (-0.48%)
Portola Pharmaceuticals: 3Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Portola Pharmaceuticals Inc. (PTLA) on Tuesday reported a loss of $49.6 million in its third quarter.

PTLA : 29.03 (-0.48%)
Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update.

PTLA : 29.03 (-0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade PTLA with:

Business Summary

Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.

See More

Key Turning Points

2nd Resistance Point 30.04
1st Resistance Point 29.60
Last Price 29.03
1st Support Level 28.46
2nd Support Level 27.76

See More

52-Week High 37.95
Fibonacci 61.8% 29.11
Last Price 29.03
Fibonacci 50% 26.38
Fibonacci 38.2% 23.65
52-Week Low 14.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar